GlobalData on MSN

Biogen’s Tysabri to be used on England’s NHS for highly active MS

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple ...

What Biogen (BIIB)'s China Review for At‑Home LEQEMBI Injections Means For Shareholders

Biogen and Eisai recently announced that Chinese regulators have accepted their Biologics License Application for a subcutaneous, at‑home injectable version of Alzheimer’s drug LEQEMBI, advancing it ...
TMCnet

Proximity Health Solutions and Biogen Named Finalists for the SCOPE '26 Participant Engagement Award

Proximity Health Solutions, in collaboration with Biogen, announces that Better Together: Sharing Our Lupus Stories has been selected as one of the four finalists for the prestigious 2026 SCOPE ...
StockStory.org on MSN

Biogen (BIIB) stock trades up, here is why

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 2.8% in the morning session after RBC Capital reiterated an "Outperform" rating and a $210 price target on the stock, naming it a ...
FiercePharma

Next Biogen CEO's most-prized expertise? Dealmaking experience, investors say

Biogen is showing CEO Michel Vountasos to the door in the aftermath of its Aduhelm debacle. As the company searches for a new leader, one skill set stands out to investors as the most-coveted piece of ...

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer an at-home injection from the ...
pharmaphorum

NICE recommends wider use of Biogen MS drug via NHS

NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with ...
ALS News Today

Qalsody shows long-term benefits in some SOD1-ALS patients: Study

Some people with SOD1-ALS experienced improvements in physical function and muscle strength after three years on Qalsody, an ...
FiercePharma

Biogen used charity giving to illegally boost multiple sclerosis drug sales, Humana lawsuit says

For years, federal prosecutors have gone after drug companies for allegedly using charity contributions as a way to boost sales. Biogen was among the pharma players to ink a federal settlement, but ...
FierceBiotech

Biogen resurrects aducanumab, arguing expanded data set supports FDA filing in Alzheimer's

Biogen is planning to file for FDA approval of its failed Alzheimer’s disease drug aducanumab. The drug flunked a futility analysis in March, but Biogen resurrected it after factoring in data ...

Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge

Discover why Biogen Inc.'s stock surged 15% in 2025, driven by Skyclarys sales. Explore its strong growth potential and ...
STAT

Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds

The downfall of Aduhelm, the first new treatment for Alzheimer’s disease in two decades, is largely the story of a drug company choosing to maximize its potential profits at the expense of patients ...